Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal

February 7, 2024

https://www.globenewswire.com/news-release/2024/02/07/2825220/0/en/Altamira-Therapeutics-Peptide-Based-Delivery-Platform-Shown-to-Enhance-Potency-of-Commonly-Used-Gene-Delivery-Method-as-Published-in-Peer-Reviewed-Journal.html

HAMILTON, BERMUDA, Feb. 07, 2024 (GLOBE NEWSWIRE) —

    

HAMILTON, BERMUDA, Feb. 7, 2024 — Altamira Therapeutics Ltd. (Nasdaq:CYTO) (“Altamira” or the “Company”), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, announced today the publication of a peer-reviewed article in the Journal of Integrative Medicine titled, “Melittin analog p5RHH enhances recombinant adeno-associated virus transduction efficiency”. This work evaluates the use of various peptides to enhance adeno-associated virus (AAV) cell transduction and was conducted by an independent research group.1 Recombinant AAVs are commonly used as carriers to introduce nucleic acids in cells for gene therapy; several AAV-based gene therapy drugs have already been approved by the U.S. Food and Drug Administration (FDA).

Read more at globenewswire.com

Related news for (CYTO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.